Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CellaVision AB ( (SE:CEVI) ) has issued an update.
CellaVision’s Nomination Committee has finalized its proposals for the 2026 Annual General Meeting, recommending a six-member board with unchanged remuneration levels and the election of former CEO Zlatko Rihter as the new chairman. The proposal retains five current directors, introduces Rihter as a new board member and chair, and reflects a bid to leverage his extensive medtech and leadership experience while ensuring continuity in governance and oversight for shareholders.
The committee notes that outgoing chair Mikael Worning will remain on the board, while current director Louise Armstrong-Denby has declined re-election, slightly reshaping the board’s composition without altering its overall size. Detailed information on the nominees and the committee’s rationale will be published on CellaVision’s website ahead of the AGM, giving investors insight into how the refreshed leadership may guide the company’s strategic direction in the competitive medical technology market.
More about CellaVision AB
CellaVision AB is a global medical technology company that develops and sells automated systems for routine analysis of blood and other body fluids used in healthcare diagnostics. Its solutions, which leverage image analysis, artificial intelligence and automated microscopy, replace manual lab work and support efficient workflows across more than 40 countries, generating SEK 759 million in sales in 2025 and targeting 15% annual growth over the cycle.
Average Trading Volume: 37,282
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.63B
Learn more about CEVI stock on TipRanks’ Stock Analysis page.